Author

Jean Bernard Marc

Institution: Gheskio Centers

Observed institution: Gheskio Centers

ORCID: 0009-0008-1428-5015

Observed ORCID: 0009-0008-1428-5015

OpenAlex ID: A5111288822

Virological and drug-resistance outcomes for people living with HIV initiating or switching to tenofovir, lamivudine, and dolutegravir in six PEPFAR-supported countries: a prospective cohort study

2025 · Jean Bernard Marc, Caitlyn McCarthy, et al. · The Lancet HIV · 7

A 3-month clofazimine–rifapentine-containing regimen for drug-susceptible tuberculosis versus standard of care (Clo-Fast): a randomised, open-label, phase 2c clinical trial

2025 · John Z Metcalfe, Isabelle R Weir, et al. · The Lancet Infectious Diseases · 7

Bictegravir, emtricitabine, and tenofovir alafenamide versus ritonavir-boosted protease inhibitor-based antiretroviral therapy in people with HIV and viral suppression on second-line therapy in Haiti: an open-label, randomised, non-inferiority trial

2025 · Patrice Severe, Samuel Pierre, et al. · The Lancet HIV · 6

Early initiation of fast‐track care for persons living with HIV initiating dolutegravir‐based regimens during a period of severe civil unrest in Port‐au‐Prince, Haiti: a pilot randomized trial

2025 · Jean Bernard Marc, Samuel Pierre, et al. · Journal of the International AIDS Society · 4

Virology Outcomes of Tenofovir-lamivudine-dolutegravir in Treatment-naïve and Virologically Suppressed Individuals Switching From an NNRTI-based Regimen: An Observational Analysis at 13 Sites

2025 · Cissy Kityo, Caitlyn McCarthy, et al. · Open Forum Infectious Diseases · 3

Works count: 6

Citation count: 34

H-index: 4

I10-index: